Shopping Cart
- Remove All
- Your shopping cart is currently empty
ARD-266 is a highly potent VHL E3 ligase-based androgen receptor (AR) PROTAC degrader, effectively inducing AR protein degradation in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines (DC50s: 0.2-1 nM).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 mg | Inquiry | Backorder | |
500 mg | Inquiry | Backorder |
Description | ARD-266 is a highly potent VHL E3 ligase-based androgen receptor (AR) PROTAC degrader, effectively inducing AR protein degradation in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines (DC50s: 0.2-1 nM). |
In vitro | ARD-266 (Compound 11; 100 nM; 1-24 hours; LNCaP and VCaP cells) reduces AR protein levels within 3 hours, achieving near-complete AR elimination after 6 hours in LNCaP cells. ARD-266 (1-10000 nM; 24 hours; LNCaP cells) also suppresses PSA, TMPRSS2, and FKBP5 gene expression in a dose-dependent manner, reducing mRNA levels by over 50% at 10 nM in LNCaP cells. |
Molecular Weight | 915.51 |
Formula | C52H59ClN6O7 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.